Successful vaginal delivery in a parturient with long QT syndrome type 2 using double-catheter epidural analgesia
A CARE-compliant case report

Hironori Ishizaki, MDa, Hiroaki Murata, MDab,∗, Takuji Maekawa, MDc, Taiga Ichinomiya, MDa, Tetsuya Hara, MDa

Abstract

Rationale: Congenital long QT syndrome (LQTS) can cause syncope or sudden death due to ventricular arrhythmia. Congenital LQTS has 3 major types, 1, 2, and 3. Life-threatening arrhythmias are triggered by emotion in patients with LQTS type 2. As patients with LQTS type 2 have a higher incidence of postnatal cardiac events, careful perinatal management especially during delivery is required. To the best of our knowledge, perinatal management of a patient with LQTS type 2 has not been properly described with consideration to its type-specific risk factors for ventricular tachyarrhythmia.

Patient concerns: A 36-year-old pregnant woman, gravid 1, para 0, with LQTS type 2 was scheduled to undergo vaginal delivery under epidural labor analgesia in the 38th week of pregnancy. No fainting episodes were reported since she began to take 40 mg of propranolol once daily at the age of 25. Despite this, we instituted maximum preventive measures for the safety of both the parturient and the fetus to minimize the risk of maternal cardiac events throughout the perinatal period.

Diagnoses: She was diagnosed with LQTS type 2 by genetic testing at the age of 25.

Interventions: Two epidural catheters were placed at levels T11–T12 and L5–S1. Injection of 0.2% ropivacaine and subsequent infusion of ropivacaine 0.1% with fentanyl (2 μg/mL) was directed through each catheter according to the stage of labor. Concurrently, landiolol, a selective and short-acting β1 receptor antagonist, was infused intravenously at a dose of 1 to 7 μg/kg/min.

Outcomes: The delivery proceeded uneventfully without pain. No adverse cardiac events were observed during the perinatal period.

Lessons: Vaginal delivery under epidural labor analgesia using 2 catheters might be a viable option for maternal perinatal care and delivery of patients with LQTS type 2.

Abbreviations: LQT1 = LQTS type 1, LQT2 = LQTS type 2, LQT3 = LQTS type 3, LQTS = long QT syndrome, QTc = QT interval corrected by the heart rate, Tdp = torsades de pointes.

Keywords: epidural labor analgesia, landiolol, long QT syndrome type 2, vaginal delivery

1. Introduction

The prevalence of congenital long QT syndrome (LQTS) is approximately 1:2000.[1,2] Congenital LQTS is caused by a mutation in the genes that encode cardiac ion channels[3] and is clinically characterized by a prolonged QT interval on electrocardiogram and polymorphic ventricular tachyarrhythmia.[4] Although most episodes of ventricular tachyarrhythmia are transient, few lead to fatal arrhythmias, such as torsades de pointes (Tdp), resulting in sudden death.[4,5] Congenital LQTS types 1, 2, and 3 (LQT1, LQT2, and LQT3, respectively) account for approximately 80% of all gene mutation-related LQTS.[6] Life-threatening arrhythmias are triggered by exercise in LQT1; emotion and auditory stimuli in LQT2,[7] and sleep/rest in LQT3 patients.[3] β-blockers are the first choice to control the QT interval and prevent Tdp in patients with congenital LQTS.[8]

Although labor-associated strong emotional and physical stress is considered a risk factor for fatal arrhythmia in pregnant women with LQTS, the appropriate management of delivery has not yet been established. Moreover, no report has described the perinatal management of LQTS patients with focus on gene mutation type-specific risk stratification. We report the case of a pregnant woman with LQT2 who underwent painless vaginal
delivery with double-catheter epidural labor analgesia and a concurrent intravenous infusion of landiolol, a selective and short-acting β1 receptor antagonist, to prevent ventricular arrhythmia.

2. Case report

The patient provided written consent, and the Ethics Committee of Nagasaki University Hospital approved this study (approval number 16122626). A 36-year-old pregnant woman (height, 158 cm; weight, 60 kg), gravida 1, para 0, with LQT2 had a history of repeated fainting on several occasions, triggered by diverse stimuli, such as hearing an alarm. At the age of 25, the QT interval corrected by the heart rate (QTc) was 500 ms, and she was diagnosed with LQT2 by genetic testing. She began to take 40 mg of propranolol once daily with good adherence. Subsequently, she did not experience any fainting episodes. Scheduled vaginal delivery under epidural labor analgesia was planned in the 38th week of pregnancy. Results of the physical examination and laboratory investigations, including hematology, biochemistry, chest radiography, and echocardiography, were normal. The electrocardiogram was normal except for a prolonged QTc (524 ms). The fetus was normal on examination. The parturient continued taking her regular dose of propranolol until the morning of delivery.

Every time the patient was taken into a procedure room, a calm environment was ensured by restricting the unnecessary entrance of medical staff. Special care was taken to keep her away from sudden and loud noises, such as ringing cell phones, monitor alarms, and the sound from the intercom broadcasts. Moreover, we talked to her in a tranquil tone throughout the procedure. An emergency cart and defibrillator were at the ready in every procedure room.

On the day prior to scheduled delivery, we placed 2 epidural catheters at T11–12 and L5–S1 in the operating room. One milliliter of 2% lidocaine was administered in each catheter to confirm proper placement of the epidural catheter and spread of local anesthetic. Loss of sensation from T8 to T10 and L5 to S1 was confirmed 15 minutes after each injection.

During delivery in the operating room, we evaluated the arterial pressure and arterial pressure-based cardiac output using the FloTrac/Vigileo system (Edwards Lifesciences, Irvine, CA) in addition to standard monitoring. Arterial blood samples were regularly analyzed for electrolytes. The fetal heart rate was measured with an intrapartum fetal monitor. Three milliliters of 0.2% ropivacaine was injected through an epidural catheter at T11–12 upon induction of labor with oxytocin. Fifteen minutes later, hypesthesia from T8 to T10 and L5 to S1 was confirmed.

Continuous intravenous infusion of oxytocin was initiated at a low dose (0.12 U/h) and then gradually increased to a maximum of 2.5 U/h with strict monitoring of the hemodynamic states of the patient and the fetus. Lithotomy position was adopted upon full cervical dilatation. Instrumental labor was applied to reduce maternal stress. The delivery proceeded uneventfully without pain, except for abdominal strain, and without anesthetic or obstetric complications. The elapsed time from the initiation of labor induction to the full dilatation of the cervix and from the full dilatation of the cervix to completion was 6 and 1 hour, respectively. During the entire delivery period, there were no significant changes in QTc, blood pressure, heart rate, cardiac index, or blood electrolyte levels. The heart rate of the baby immediately after birth was 160 beats per minute. Apgar scores were 9 and 10 at 1 and 5 minutes following delivery, respectively. The estimated blood loss, including amniotic fluid, was 500 mL, the urine output was 1550 mL, and the total fluid volume of intravenous infusion was 2390 mL during delivery. No postpartum analgesics were required. Landiol infusion was maintained following delivery at a rate of 3 μg/kg/min until the patient resumed oral propranolol. The post-parturition clinical course was uneventful, and no ventricular arrhythmia was observed throughout the perinatal period. Overall, the patient was completely satisfied with the management of vaginal delivery with epidural analgesia using double epidural catheter and the perinatal management to avoid cardiac events related to LQT2 with careful attention and adequate medication.
visceral pain from cervical dilation, while infusion through the lower catheter at L5–S1 mainly addresses somatic pain associated with dilation of the birth canal. Delivery under epidural analgesia can cause uterine inertia or prolonged delivery, resulting in conversion to cesarean section. To address this concern without sacrificing the quality of analgesia, we planned to reduce or discontinue the local anesthetic infusion via the upper catheter, independent of the use of the lower catheter, when uterine inertia was suspected.

Landiolol, a selective and short-acting β1 receptor antagonist, has been reported to be useful for heart rate control during birth because it had no inhibitory effects on uterine contraction through β2 receptor blockade.[15] The administration of β-blockers had been effective in preventing ventricular arrhythmia in the present patient, and patients with LQT2 have a high incidence of postnatal heart accidents[13]; thus, we prophylactically administered landiolol from induction of labor until oral propranolol could be resumed following delivery. No adverse events related to the use of landiolol were observed.

Oxytocin is a drug that induces uterine contraction and prevents bleeding during delivery. Bolus injection of oxytocin is known to cause QTc prolongation; hence, oxytocin is considered a potentially arrhythmogenic agent among patients at risk of Tdp. Slow administration of oxytocin has been recommended.[16,19] Herein, oxytocin infusion was initiated at a low rate and gradually titrated, resulting in appropriate uterine contraction without QTc prolongation. As a limitation of this case report, we did not directly show the preventive effect of each intervention. For example, single epidural catheter might be enough to provide sufficient analgesia during vaginal delivery. Likewise, only regular dose of propranolol until the morning of delivery might be effective during vaginal delivery without intravenous landiolol. We provided the maximum preventive measures for the safety of both the parturient and the fetus to minimize the risk of maternal cardiac events throughout the perinatal period.

4. Conclusion
We achieved painless vaginal delivery for a parturient with LQT2 using double-catheter epidural analgesia. Moreover, careful infusion of oxytocin and landiolol was useful in avoiding perinatal ventricular arrhythmias.

Acknowledgments
The authors would like to thank Editage (www.editage.com) for English language editing.

Author contributions
Conceptualization: Hironori Ishizaki, Hiroaki Murata.
Data curation: Hironori Ishizaki, Takuji Maekawa.
Supervision: Hiroaki Murata, Tetsuya Hara.

Writing – original draft: Hironori Ishizaki, Takuji Maekawa.
Writing – review & editing: Hiroaki Murata, Taiga Ichinomiya, Tetsuya Hara.

References
[1] Schwartz PJ, Stramba-Badiale M, Crotti L, et al. Prevalence of the congenital long-QT syndrome. Circulation 2009;120:1761–7.
[2] Yoshinaga M, Ushinohama H, Sato S, et al. Electrocardiographic screening of 1-month-old infants for identifying prolonged QT intervals. Circ Arrhythm Electrophysiol 2013;6:932–8.
[3] Schwartz PJ, Priori SG, Spazzolini C, et al. Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. Circulation 2001;103:89–95.
[4] Schwartz PJ, Moss AJ, Vincent GM, Crampton RS. Diagnostic criteria for the long QT syndrome. An update. Circulation 1993;88:782–4.
[5] Kies SJ, Pabelick CM, Hurley HA, White RD, Ackerman MJ. Anesthesia for patients with congenital long QT syndrome. Anesthesiology 2005;102:204–10.
[6] O’Hare M, Maldonado Y, Munro J, Ackerman MJ, Ramakrishna H, Soriaj D. Perioperative management of patients with congenital or acquired disorders of the QT interval. Br J Anaesth 2018;120:629–44.
[7] Wilde AA, Jongbloed RJ, Doevendans PA, et al. Auditory stimuli as a trigger for arrhythmic events differentiate HERG-related (LQT2) patients from KVLIQT1-related patients (LQT31). J Am Coll Cardiol 1999;33:327–32.
[8] Moss AJ, Zareba W, Hall WJ, et al. Effectiveness and limitations of beta-blocker therapy in congenital long-QT syndrome. Circulation 2000;101:616–23.
[9] Goldenberg I, Bradley J, Moss A, et al. Beta-blocker efficacy in high-risk patients with the congenital long-QT syndrome types 1 and 2: implications for patient management. J Cardiovasc Electrophysiol 2010;21:893–901.
[10] Priori SG, Napolitano C, Schwartz PJ, et al. Association of long QT syndrome loci and cardiac events among patients treated with beta-blockers. JAMA 2004;292:1341–4.
[11] Priori SG, Schwartz PJ, Napolitano C, et al. Risk stratification in the long-QT syndrome. N Engl J Med 2003;348:1866–74.
[12] Moss AJ, Schwartz PJ, Crampton RS, et al. The long QT syndrome. Prospective longitudinal study of 328 families. Circulation 1991;84:1136–44.
[13] Seth R, Moss AJ, McNitt S, et al. Long QT syndrome and pregnancy. J Am Coll Cardiol 2007;49:1092–8.
[14] Hashimoto E, Kojima A, Kitagawa H, Matsuura H. Anesthetic management of a patient with type 1 long QT syndrome using combined epidural-spinal anesthesia for Caesarean section: perioperative approach based on ion channel function. J Cardiothorac Vasc Anesth 2020;34:465–9.
[15] Kubo K, Murao K, Nakao S, Kanoda T, Yamada M, Shingu K. Successful management of cesarean section in a patient with Romano-Ward syndrome using landiolol, a selective and short-acting beta1 receptor antagonist. J Anesth 2005;19:174–6.
[16] Hodgkinson P, McAtamney D. Combined spinal-epidural anaesthesia for caesarean section in a patient with long QT syndrome. Int J Obstet Anesth 2008;17:78–80.
[17] Behl S, Wauchob TD. Long QT syndrome: anaesthetic management at delivery. Int J Obstet Anesth 2005;14:347–50.
[18] Martinez G, Powell L. Dual epidural catheter therapy for labor analgesia in a patient with prior lumbar spine surgery. Int J Obstet Anesth 2020;42:118–20.
[19] Charbit B, Funck-Brentano C, Samain E, Jannier-Guilhou V, Albaladejo P, Marty J. QT interval prolongation after oxytocin bolus during surgical induced abortion. Clin Pharmacol Ther 2004;76:359–64.